Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.

Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, Shoup TM, Williams SA, Rubin RH.

J Pharmacol Exp Ther. 1996 Nov;279(2):939-47.

PMID:
8930203
[PubMed - indexed for MEDLINE]
2.

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.

Am J Psychiatry. 2004 May;161(5):818-25.

PMID:
15121646
[PubMed - indexed for MEDLINE]
3.

Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis.

Petit-Taboué MC, Landeau B, Osmont A, Tillet I, Barré L, Baron JC.

J Nucl Med. 1996 Jan;37(1):95-104.

PMID:
8544011
[PubMed - indexed for MEDLINE]
Free Article
4.

Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.

Petit-Taboué MC, Landeau B, Barré L, Onfroy MC, Noël MH, Baron JC.

J Nucl Med. 1999 Jan;40(1):25-32.

PMID:
9935052
[PubMed - indexed for MEDLINE]
Free Article
5.

A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone.

Blin J, Sette G, Fiorelli M, Bletry O, Elghozi JL, Crouzel C, Baron JC.

J Neurochem. 1990 May;54(5):1744-54.

PMID:
2182776
[PubMed - indexed for MEDLINE]
6.

Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions.

Parsey RV, Slifstein M, Hwang DR, Abi-Dargham A, Simpson N, Mawlawi O, Guo NN, Van Heertum R, Mann JJ, Laruelle M.

J Cereb Blood Flow Metab. 2000 Jul;20(7):1111-33.

PMID:
10908045
[PubMed - indexed for MEDLINE]
Free Article
7.

Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.

Biver F, Goldman S, Luxen A, Monclus M, Forestini M, Mendlewicz J, Lotstra F.

Eur J Nucl Med. 1994 Sep;21(9):937-46.

PMID:
7995287
[PubMed - indexed for MEDLINE]
8.

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.

Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R.

Psychopharmacology (Berl). 1998 Jan;135(2):119-26.

PMID:
9497016
[PubMed - indexed for MEDLINE]
9.

Modeling [18 F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection.

Costes N, Merlet I, Zimmer L, Lavenne F, Cinotti L, Delforge J, Luxen A, Pujol JF, Le Bars D.

J Cereb Blood Flow Metab. 2002 Jun;22(6):753-65.

PMID:
12045674
[PubMed - indexed for MEDLINE]
Free Article
10.

Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]flumazenil.

Price JC, Mayberg HS, Dannals RF, Wilson AA, Ravert HT, Sadzot B, Rattner Z, Kimball A, Feldman MA, Frost JJ.

J Cereb Blood Flow Metab. 1993 Jul;13(4):656-67.

PMID:
8391018
[PubMed - indexed for MEDLINE]
Free Article
11.

A PET study of brain 5-HT2 receptors and their correlation with platelet 5-HT2 receptors in healthy humans.

Yatham LN, Steiner M, Liddle PF, Shiah IS, Lam RW, Zis AP, Coote M.

Psychopharmacology (Berl). 2000 Sep;151(4):424-7.

PMID:
11026749
[PubMed - indexed for MEDLINE]
12.

Modeling alternatives for cerebral carbon-11-iomazenil kinetics.

Buck A, Westera G, vonSchulthess GK, Burger C.

J Nucl Med. 1996 Apr;37(4):699-705.

PMID:
8691270
[PubMed - indexed for MEDLINE]
Free Article
13.

Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.

Corripio I, Catafau AM, Perez V, Puigdemont D, Mena E, Aguilar Y, Carrió I, Alvarez E.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):91-6. Epub 2004 Nov 23. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1186.

PMID:
15610950
[PubMed - indexed for MEDLINE]
14.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
[PubMed - indexed for MEDLINE]
15.

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, Gunn KP, Brannick LY, Frackowiak RS.

Psychopharmacology (Berl). 1996 Mar;124(1-2):141-7.

PMID:
8935809
[PubMed - indexed for MEDLINE]
16.

Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB.

Arch Gen Psychiatry. 2002 Jun;59(6):514-20.

PMID:
12044193
[PubMed - indexed for MEDLINE]
17.

Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.

Ohno Y, Ishida-Tokuda K, Ishibashi T, Sakamoto H, Tagashira R, Horisawa T, Yabuuti K, Matsumoto K, Kawabe A, Nakamura M.

Pol J Pharmacol. 1997 Aug;49(4):213-9. Review.

PMID:
9437764
[PubMed - indexed for MEDLINE]
18.

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S.

Am J Psychiatry. 1997 Nov;154(11):1525-9.

PMID:
9356559
[PubMed - indexed for MEDLINE]
19.

Positron emission tomographic analysis of central dopamine D1 receptor binding in normal subjects treated with the atypical neuroleptic, SDZ MAR 327.

Christian BT, Babich JW, Livni E, Alpert NM, Bonab AA, Munconi L, Polinski R, Rubin RH, Fischman AJ.

Int J Mol Med. 1998 Jan;1(1):243-7.

PMID:
9852226
[PubMed - indexed for MEDLINE]
20.

Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Mäcke HR, Eisenhut M, Debus J, Haberkorn U.

J Nucl Med. 2005 May;46(5):763-9.

PMID:
15872348
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk